HC Wainwright Reaffirms Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $60.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 69.09% from the company’s previous close.

Several other analysts also recently commented on COLL. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Needham & Company LLC dropped their price objective on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Finally, Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $35.49 on Friday. The stock’s fifty day simple moving average is $43.26 and its 200 day simple moving average is $41.89. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. The company has a market capitalization of $1.13 billion, a PE ratio of 20.75 and a beta of 0.67. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The business had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. During the same period in the previous year, the firm posted $1.77 earnings per share. The firm’s revenue was up 12.9% on a year-over-year basis. On average, research analysts predict that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the sale, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. The trade was a 41.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Dieter sold 13,976 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Group One Trading LLC acquired a new position in Collegium Pharmaceutical during the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares during the last quarter. Federated Hermes Inc. grew its position in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter worth about $61,000.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium agreed to acquire AZSTARYS from Corium, adding a differentiated ADHD medicine to its portfolio; company says the asset is expected to generate over $50M in pro‑forma net revenue in H2 2026, offers patent protection into 2037, and the deal is expected to be immediately accretive to adjusted EBITDA. Collegium to Acquire AZSTARYS from Corium Therapeutics (GlobeNewswire)
• Positive Sentiment: Sell‑side support strengthened: HC Wainwright reaffirmed a Buy with a $60 PT and Needham reaffirmed Buy with a $56 PT — both imply substantial upside vs. the recent share price, which can underpin investor confidence. Analyst Coverage (Benzinga)
• Neutral Sentiment: Conference call and management discussion transcripts are available for investors seeking details on deal economics and integration plans. Acquisition Discussion Transcript (Seeking Alpha)
• Neutral Sentiment: FDA news elsewhere in the pharma sector: PharmExec reports approval of Wegovy HD (Novo Nordisk) — relevant for sector context but not directly tied to Collegium’s ADHD/pain-focused franchise. FDA Approves Wegovy HD (PharmExec)
• Neutral Sentiment: Public press coverage shows deal price described with varying figures (reports cite up to $785M and also $650M headlines) — read releases for definitive terms. Collegium to buy AZSTARYS for up to $785M (MSN)
• Negative Sentiment: The acquisition costs and financing raise near‑term financial risk: the deal is being funded from cash on hand plus a previously announced $300M delayed‑draw term loan, which increases leverage for a company that already shows a relatively high debt/equity ratio; investors may worry about cash burn, integration execution and balance‑sheet pressure. Deal Coverage (FiercePharma)
• Negative Sentiment: Recent quarterly results (Feb. 26) showed a slight revenue and EPS miss vs. consensus, which combined with the large acquisition outlay can pressure near‑term sentiment as investors await proof the deal accelerates growth. Earnings Summary (Benzinga)
• Neutral Sentiment: Reported short‑interest data appears anomalous (shows zero shares), so it does not provide a meaningful read into market positioning at this time.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.